Tobin W Juvenal, Chief Commercial Officer of Castle Biosciences Inc., filed a Form 4 on September 16, 2026, reporting the sale of common stock on September 14 and September 15, 2026, pursuant to a Rule 10b5-1 plan.

Key Highlights

  • First sale: 3,306 shares disposed of on September 14, 2026, at a weighted-average price of $32.324 per share.
  • Second sale: 3,294 shares disposed of on September 15, 2026, at a weighted-average price of $35.142 per share.
  • Remaining ownership: 58,584 shares of common stock held directly following both transactions.
  • Rule 10b5-1 plan: Both sales were made pursuant to a plan adopted by the reporting person on May 28, 2026.
  • Multiple trades: Each transaction was executed across multiple trades; September 14 prices ranged from $32.180 to $32.445, and September 15 prices ranged from $35.000 to $35.380.

Castle Biosciences CCO Share Disposals Under Pre-Established Trading Plan

According to the filing, Tobin W Juvenal, serving as Chief Commercial Officer of Castle Biosciences Inc. (NASDAQ:CSTL), reported two separate disposals of common stock over consecutive trading days. The Form 4 was filed on September 16, 2026, and the transactions are identified with transaction code "S," indicating open-market sales.

The filing discloses that on September 14, 2026, the reporting person sold 3,306 shares at a weighted-average price of $32.324, with individual trade prices ranging from $32.180 to $32.445 inclusive. Following that transaction, beneficial ownership stood at 61,878 shares. On September 15, 2026, an additional 3,294 shares were sold at a weighted-average price of $35.142, with individual trade prices ranging from $35.000 to $35.380 inclusive, reducing directly held beneficial ownership to 58,584 shares.

Both transactions were executed under a Rule 10b5-1 trading plan that the reporting person adopted on May 28, 2026, as noted in the filing's explanation of responses. The filing further states that the reporting person "undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected." The form was signed by Frank Stokes as attorney-in-fact on September 16, 2026. No derivative securities transactions were reported.

What Was Disclosed

The filing reports two open-market sales of Castle Biosciences common stock by the Chief Commercial Officer on September 14 and 15, 2026, totaling 6,600 shares sold under a pre-established Rule 10b5-1 plan, with 58,584 shares remaining directly owned.